medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2017, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2017; 33 (1)

Treatment of acute promielocytic leukemia with arsenic trioxide and trans-retinoic acid

Hernández PC

Language: Spanish
References: 39
Page: 1-13
PDF size: 296.29 Kb.


ABSTRACT

Introduction: In the last 25-30 years the treatment of acute promyelocytic leukemia has been proposed by methods of induction of cell differentiation.
Method: We compared some of the results of two protocols for the treatment of acute promyelocytic leukemia, LPM-TOA in which the first line drug was arsenic trioxide and LPM-03 in which transretinoic acid was used with Rubidomycin in induction to remission.
Results: With LPM-TOA hematologic remission was achieved in 83.3% of patients at 43.22 days on average, the cell differentiation syndrome was present in 6 cases (9.1%), the event free survival at 60 months was 89.26%, as was overall survival, due to the fact that there were no relapses during the study period, whereas with the LPM-03 protocol hematologic remission was achieved in 96% of the patients at 44.35 days; 5 patients (10%) presented the cell differentiation syndrome, the events free survival at 60 months was 75% and the overall survival was 83.3%. In the comparison there was no statistical significance, but not in the disease-free survival at 60 months in which the LPM-TOA was 100% while in the LPM-03 it was 78% (p = 0.001).
Conclusions: Arsenic was found to be one more option to manage the disease, both in relapse and in cases of recent diagnosis. With these results, our country shows figures of event-free survival at 5 years of diagnosis and cure comparable to those of the most developed countries worldwide.


REFERENCES

  1. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113(16):3655-65.

  2. Brown G, Hughes P. Retinoid Differentiation Therapy for Common Types of AcuteMyeloid Leukemia. Leuk Res Treat. 2012;2012.

  3. Mesa JR, Espinosa E, Losada R, Hernández C, Plasencia A, Hernández P. Parotid and central nervous system relapse during complete hematologic remision in acute promyelocytic leukemia. Haematologica. 1999;84(6):565-6.

  4. Hernandez P, Carnot J, Dorticos E, Espinosa E, González A, Rodríguez I. All-trans retinoic acid in acute promyelocytic leukemia: preliminary results in Cuba. Ann Hematol. 1992;65(3):121-23.

  5. Hernández Ramírez P, Carnot Uría J, Dorticós Balea E, Espinosa Martínez E, González Otero A, Hernández Pérez G, et al. Tratamiento de la leucemia promielocítica con ácido retinoico. Rev Cub Hematol Inmunol Hemoter [Internet]. 1995(Accedido Julio 26, 2016);11(1) : Disponible en: http://bvs.sld.cu/revistas/hih/vol11_1_95/hih06195.htm

  6. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505-15.

  7. Hernández Ramírez P, Martínez Antuña G, Espinosa Martínez E, Losada Buchillón R, González Otero A, Machín García S, et al . Tratamiento de la leucemia promielocítica con ácido transretinoico y quimioterapia intensiva: Evolución clínica y molecular. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2002 Ago [citado 2017 Ene 05] ;18(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892002000200002&lng=es.

  8. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood. 1997;89(9):3354-60.

  9. Hernández Padrón C, Machín García S, Gómez Carril M, Ramón Rodriguez L, Losada Buchillón R, Agramonte Llánes O, et al. Uso del trióxido de arsénico (Arsenin ®) en el tratamiento de la leucemia promielocítica en recaída. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2007 Abr [citado 2017 Ene 05] ;23(1): . Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892007000100009&lng=es.

  10. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852-60.

  11. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99(3):759-67.

  12. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469-73.

  13. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, et al. Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data. J Clin Oncol. 2010;28(24):3866-71.

  14. Hernández-Padrón C, Gil-Agramonte M, Espinosa-Martínez E, González-Otero A, Arencibia-Núñez A, Hernández-Ramírez P. Tratamiento de la leucemia promielocítica al inicio de la enfermedad con trióxido de arsénico (ARSENIN®). Informe preliminar. Rev Cubana Hematol Inmunol Hemoter. 2011;27(2):267-70.

  15. Hernández-Padrón C, Dorticós-Balea E, Machín-García S, Menéndez-Veitía A, González-Otero A, Avila-Cabrera O, et al. Leucemia promielocítica de reciente diagnóstico. Tratamiento con trióxido de arsénico de producción nacional. (ARSENIN®). Rev Cub Hematol, Inmunol Hemoter 2014;30(4):346-59.

  16. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med. 1992;12:170-1.

  17. Rao Y, Li RH, Zhang DQ. A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci China Life Sci. 2013;56(6):495-502.

  18. Huang H, Qin Y, Xu R, You X, Teng R, Yang L, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leuk Res. 2012 Jul;36(7):841-5.

  19. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. Alltrans- retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80.

  20. Park JH. ATRA plus arsenic gets another ''A'' in APL. Blood. 2012;120(8):1535-6.

  21. Chen L, Han F, Qu H, Yan H, Ren L, Yang S. Combination therapy with 5-amino-4- imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway. Pharmazie. 2013 Feb;68(2):117-23.

  22. Chen L, Wang J, Hu X, Xu X. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Hematology. 2014 Jun;19(4):202-7. doi: 10.1179/1607845413Y.0000000118.

  23. Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, et al. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res. 2013;37(1):37-42.

  24. Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013 Jan 1;119(1):115-25.

  25. Cull EH; AltmanJK. Contemporary Treatment of APL. Curr Hematol Malig Rep. 2014 2014;9(2):193-201.

  26. Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q. ATO/ATRA/Anthracycline-Chemotherapy Sequential Consolidation Achieves Long-Term Efficacy in Primary Acute Promyelocytic Leukemia. PLoS ONE 2014;9(8):e104610.

  27. Chen L; Wang J; Hu X; Xu X. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Hematology. 2014;19(4):202 - 8.

  28. Park JH, Tallman MS. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park). 2011 Jul;25(8):733-41.

  29. Pagoni M, Garofalaki M, Panitsas F, Manola K, Psarra K, Economopoulos P, et al. Acute Promyelocytic Leukemia: an Experience on 95 Greek Patients Treated in the All- Trans-Retinoic Acid Era. Mediterr J Hematol Infect Dis 2011;3 (1):2011053.

  30. Masetti R, Vendemini F, Zama D, Biagi C, Gasperini P, Pession A. All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. Exp Review of Anticancer Ther. 2012;12(9):1191-204.

  31. Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M. Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia. J Clin Oncol 2011;29(20):2753-57.

  32. Alimoghaddam K. A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia. IJHOSCR. 2014;8(3):44-54.

  33. Coombs CC; Tavakkoli M; Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future Blood Cancer J. 2015;5(e304).

  34. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol. 2011;156: 24-36.

  35. Tallman M, Lo-Coco F, Kwaan H, Sanz M, Gore S. Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia. Clin Adv Hematol Oncol. 2011 Feb;9(2):1-16.

  36. Shindo M, Ikuta K, Addo L, Ito S, Fujiya M, Torimoto Y, et al. Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia. Case Rep Hematol. 2012;2012:908196.

  37. Li J; Zhu H; Hu J; Mi J; Chen S; Chen Z. Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. Int J Hematol 2014;100:38-50.

  38. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008 Jun 19;453(7198):1072-8.

  39. dos Santos GA; Kats L; Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013;210(13):2793-802.




2020     |     www.medigraphic.com